Reprogramming the tumor microenvironment to enhance adoptive cellular therapy

被引：75

作者：

Beavis, Paul A. ^{[1
,2
]}

Slaney, Clare Y. ^{[1
,2
]}

Kershaw, Michael H. ^{[1
,2
,3
,4
]}

Gyorki, David ^{[5
,6
]}

Neeson, Paul J. ^{[1
,2
]}

Darcy, Phillip K. ^{[1
,2
,3
,4
]}

机构：

[1] Peter MacCallum Canc Ctr, Canc Immunol Program, East Melbourne, Vic, Australia

[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3010, Australia

[3] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia

[4] Monash Univ, Dept Immunol, Clayton, Vic, Australia

[5] Peter MacCallum Canc Ctr, Div Canc Surg, East Melbourne, Vic, Australia

[6] Univ Melbourne, Dept Surg, Melbourne, Vic 3010, Australia

来源：

SEMINARS IN IMMUNOLOGY | 2016年 / 28卷 / 01期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

Adoptive cellular therapy; Chimeric antigen receptor; Immunosuppression; Cancer; Immunotherapy; CHIMERIC ANTIGEN RECEPTOR; REGULATORY T-CELLS; COLON-CANCER ERADICATION; IN-VIVO PERSISTENCE; SUPPRESSOR-CELLS; ANTITUMOR EFFICACY; INFILTRATING LYMPHOCYTES; MYELOID CELLS; CHECKPOINT BLOCKADE; IMMUNE-RESPONSE;

D O I：

10.1016/j.smim.2015.11.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

The frontiers of cancer immunotherapy are extending in terms of both the range of cancer types that can potentially be targeted and the types of therapeutics that are in clinical development. The use of adoptive cellular therapy (ACT) and its derivative, chimeric antigen receptor (CAR) T cells, is currently limited to hematological malignancies and immunogenic cancers such as melanoma and renal cell carcinoma. Although ACT utilizing ex vivo expanded tumor-infiltrating lymphocytes (TIL) or engineered CAR/TCR T cells have undergone clinical trials for other solid cancers, their efficacy to date has been limited. This may be due, in part, to the immunosuppressive nature of the tumor microenvironment. The development of novel combination approaches which target the immunosuppressive network engineered by tumors has raised the possibility of using ACT for a broader range of cancers. This review summarizes the potential of such strategies and outlines the clinical relevance of these observations. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：64 / 72

页数：9

共 185 条

[1]

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes [J].

Abate-Daga, Daniel ;

Hanada, Ken-ichi ;

Davis, Jeremy L. ;

Yang, James C. ;

Rosenberg, Steven A. ;

Morgan, Richard A. .

BLOOD, 2013, 122 (08) :1399-1410

[2]

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity [J].

Adusumilli, Prasad S. ;

Cherkassky, Leonid ;

Villena-Vargas, Jonathan ;

Colovos, Christos ;

Servais, Elliot ;

Plotkin, Jason ;

Jones, David R. ;

Sadelain, Michel .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)

[3]

The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor- receptor on dendritic cells potentiates tumour antigen-specific CD8+ T cell immunity [J].

Ahn, Y. -H. ;

Hong, S. -O. ;

Kim, J. H. ;

Noh, K. H. ;

Song, K. -H. ;

Lee, Y. -H. ;

Jeon, J. -H. ;

Kim, D. -W. ;

Seo, J. H. ;

Kim, T. W. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 181 (01) :164-178

[4]

Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[5]

Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer [J].

Alizadeh, Darya ;

Trad, Malika ;

Hanke, Neale T. ;

Larmonier, Claire B. ;

Janikashvili, Nona ;

Bonnotte, Bernard ;

Katsanis, Emmanuel ;

Larmonier, Nicolas .

CANCER RESEARCH, 2014, 74 (01) :104-118

[6]

Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape [J].

Anderson, Ana C. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (05) :393-398

[7]

Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity [J].

Ankri, Chen ;

Shamalov, Katerina ;

Horovitz-Fried, Miryam ;

Mauer, Shmuel ;

Cohen, Cyrille J. .

JOURNAL OF IMMUNOLOGY, 2013, 191 (08) :4121-4129

[8]

Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia [J].

Baba, Junko ;

Watanabe, Satoshi ;

Saida, Yu ;

Tanaka, Tomohiro ;

Miyabayashi, Takao ;

Koshio, Jun ;

Ichikawa, Kosuke ;

Nozaki, Koichiro ;

Koya, Toshiyuki ;

Deguchi, Katsuya ;

Tan, Chunrui ;

Miura, Satoru ;

Tanaka, Hiroshi ;

Tanaka, Junta ;

Kagamu, Hiroshi ;

Yoshizawa, Hirohisa ;

Nakata, Ko ;

Narita, Ichiei .

BLOOD, 2012, 120 (12) :2417-2427

[9]

Bachanova Veronika, 2014, Critical Reviews in Oncogenesis, V19, P133

[10]

Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street [J].

Barrett, David M. ;

Grupp, Stephan A. ;

June, Carl H. .

JOURNAL OF IMMUNOLOGY, 2015, 195 (03) :755-761

← 1 2 3 4 5 6 7 8 9 10 →